Sign In
Buy ZYME
$24.35
+0.240 (+1.00%)
At Close: Jun 03, 2026
Zymeworks, Jazz agree to licensing deal for cancer drug
08:38am, Wednesday, 19'th Oct 2022
Shares of Zymeworks Inc. ZYME, -2.43% gained 8.4% in premarket trading on Wednesday after the company announced a licensing deal with Jazz Pharmaceuticals plc JAZZ, -0.41% for its cancer drug, zanidat
Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab
06:07am, Wednesday, 19'th Oct 2022
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics,
Why Laser Photonics Shares Surged By Around 19%; Here Are 70 Biggest Movers From Friday
09:21am, Monday, 17'th Oct 2022 Benzinga
Gainers
Agrify Corporation (NASDAQ: AGFY) climbed 53.8% to close at $1.45.
FedNat Holding Company (NASDAQ: FNHC) gained 48% to settle at $0.52.
IMARA Inc. (NASDAQ: IMRA) shares climbed 46.9% to close
Dow Dips 375 Points; S&P 500 Down Over 2%
06:33pm, Friday, 14'th Oct 2022 Benzinga
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping around 375 points on Friday.
The Dow traded down 1.25% to 29,662.76 while the NASDAQ fell 2.68% to 10,363.83. The S&P 50
Why Morgan Stanley Shares Are Trading Lower, Here Are 43 Stocks Moving In Friday's Mid-Day Session
04:24pm, Friday, 14'th Oct 2022 Benzinga
Gainers
Intelligent Living Application Group Inc. (NASDAQ: ILAG) surged 77.7% to $9.35.
Gravitas Education Holdings, Inc. (NASDAQ: GEHI) shares jumped 66% to $24.90.
Avenue Therapeutics, Inc. (NASDAQ
Nasdaq Tumbles Over 200 Points; Crude Oil Falls Sharply
04:05pm, Friday, 14'th Oct 2022 Benzinga
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 200 points on Friday.
The Dow traded down 0.74% to 29,817.07 while the NASDAQ fell 2.09% to 10,426.14. The
Wells Fargo, JPMorgan, Citigroup And Some Other Big Stocks Moving Higher On Friday
03:25pm, Friday, 14'th Oct 2022 Benzinga
U.S. stocks traded lower, with the Dow Jones gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session.
Gravitas Education Holdings, Inc. (NASDAQ: GEHI) sh
Uber, Lyft, AZZ And Other Big Losers From Tuesday
08:46am, Wednesday, 12'th Oct 2022 Benzinga
U.S. stocks closed mixed with the Nasdaq Composite dropping more than 100 points on Tuesday. Here is the list of some big stocks recording losses in the previous session.
AZZ Inc. (NYSE: AZZ) shares
Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day
08:30am, Monday, 03'rd Oct 2022
VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announ
Denali Therapeutics Inc. (DNLI) Moves 17.7% Higher: Will This Strength Last?
11:30am, Thursday, 29'th Sep 2022 Zacks Investment Research
Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
09:16am, Wednesday, 07'th Sep 2022 Benzinga
Gainers
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.
IVERIC bio, Inc. (NASDAQ: ISEE) rose 66.3% to close at $15.70
Zymeworks Inc. (ZYME) CEO Ken Galbraith on Q2 2022 Results - Earnings Call Transcript
07:43pm, Saturday, 06'th Aug 2022
Zymeworks Inc. (NYSE:ZYME ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Jack Spinks - Associate Director of Investor Relations Ken Galbraith - Chair and CEO Dr. Neil
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
12:35am, Friday, 05'th Aug 2022 Zacks Investment Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -4.30% and 34.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
09:49pm, Thursday, 04'th Aug 2022
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -4.30% and 34.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Announces Participation in Upcoming Investor Conferences
08:30am, Monday, 01'st Aug 2022
VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announ
